Basic Information

Gene symbol ERBB2 Synonyms CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description erb-b2 receptor tyrosine kinase 2

GTO ID GTC2529
Trial ID NCT04660929
Disease Breast Cancer | Ovarian Cancer | Lung Small Cell Carcinoma | Endometrial Cancer | Stomach Cancer | Small Cell Carcinoma | Lung Non-Small Cell Carcinoma | Squamous Cell Carcinoma | Hepatocellular Carcinoma | Malignant Neoplasm | Prostate Cancer | Bladder Cancer | Biliary Tract Cancer | Pancreatic Cancer | Head and Neck Cancer | Transitional Cell Carcinoma | Ovarian Epithelial Carcinoma | HER2-Receptor Positive Breast Cancer | Adenocarcinoma | Colorectal Cancer | Bile Duct Cancer
Altered gene HER2
Therapeutic/Target gene Target gene
TherapyCAR-M cell
Treatment CT-0508
PhasePhase1
Recruitment statusRecruiting
TitleCAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Year2021
CountryUnited States
Company sponsorCarisma Therapeutics Inc
Other ID(s)101
Vector information
Vectoradenovirus
ConstructHER2-specific CAR-M

Clinical Result

Cohort1: IV
Administration route intravenous infusion
Dosage Group 1: 5E8 cells at Day 1, 1.5E9cells at Day 3, 3E9cells at Day 5; Group 2: 5E9 cells at Day 1
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
References DOI: 10.1200/JCO.2023.41.16_suppl.TPS2666
Cohort2: IP
Administration route intraperitoneal infusion
Dosage Group 1: 5E8 cells at Day 1, 1E9 cells at Day 3, 1.5E9 cells at Day 5; Group 2: 1.5E9 cells at Day 1, 2E9 cells at Day 3, remaining cells at Day 5; Group 3: 2.5E9 cells at Day 1, 2.5E9 cells at Day 3; Group 4, 5E9 cells at Day 1
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
References DOI: 10.1200/JCO.2023.41.16_suppl.TPS2666
Cohort3: IV_Pembrolizumab
Administration route intravenous infusion
Dosage Regimen Level 1: Day 1: (5E8) cells; Regimen Level 1: Day 3: (1.5E9) cells; Regimen Level 1: Day 5: (3E9) cells; Regimen Level 2: Day 1: (5E8) cells; Regimen Level 2: Day 3: (1.5E9) cells; Regimen Level 2: Day 5: (3E9) cells; Regimen Level 3: Day 1: (5E9) cells
Donor type Autologous
Age Adult, Older_Adult
Lymph depletion Yes
References DOI: 10.1200/JCO.2023.41.16_suppl.TPS2666

Relationship Graph

Overview of Knowledge Graph